{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 42,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/14",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.019,
        "w": 0.242,
        "x": 0.715,
        "y": 0.872
      },
      "kind": "list",
      "text": "✓ Completed ◌ Ongoing X Discontinued",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99e566bd-df0d-4d42-8ed5-216408a0da75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.019,
        "w": 0.56,
        "x": 0.06,
        "y": 0.872
      },
      "kind": "list",
      "text": "* Failed as oral/systemic treatments in retina due to dose limiting toxicity",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df18baec-6cd3-4711-bc5b-6cb785adf784",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.176,
        "x": 0.781,
        "y": 0.903
      },
      "kind": "list",
      "text": "*Trials to Support Approval\n1 Panorama Clinical Trial\n2 Protocol I & T and Rise & Ride",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2618b57-582e-4010-ae1e-a36dc56c60e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.769,
        "x": 0.049,
        "y": 0.105
      },
      "kind": "paragraph",
      "text": "Eylea®/Lucentis® Approved, But Not Used in Patients with NPDR; Rarely Used in Mild PDR",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d74a99cb-99ba-4352-8117-4094758e132d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.46,
        "x": 0.12,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Company websites and www.clinicaltrials.gov (as of October 31, 2023)\nEylea® is trademark of Regeneron and Lucentis® is trademark of Genentech",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41bce886-bd45-45b0-b6b5-b5e4ec1f8445",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.63,
        "w": 0.897,
        "x": 0.06,
        "y": 0.183
      },
      "kind": "table",
      "text": "Company Drug Target/MOA Route of Administration Phase 1 Phase 2 Phase 3 Commercial Regeneron Eylea® (aflibercept) VEGF-A/B; PIGF Intravitreal ✓ ✓ ✓ ✓*1 Roche Lucentis® (ranibizumab) VEGF-A Intravitreal ✓ ✓ ✓ ✓*2 Kodiak KSI-301 (Tarcocimab) VEGF Intravitreal ✓ N/A ◌ Eyepoint Pharmaceuticals EYP-1901 Voloronib* (TKI) Intravitreal ✓ ◌ Boehringer Ingelheim BI 764524 Anti-Sema3A Ischemia modulator Intravitreal ✓ ◌ Ocular Therapeutix OTX-TKI Axitinib* (TKI) Intravitreal ✓ ◌ Regenxbio RGX-314 AAV8-VEGF Suprachoroidal (Gene Therapy) ✓ ✓",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b27f097e-3e53-4a51-a2e3-55a3cb62a0f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.901,
        "x": 0.049,
        "y": 0.047
      },
      "kind": "title",
      "text": "Landscape of Invasive Therapies (IVT/Suprachoroidal) for Diabetic Retinopathy",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09af1fa3-ed9f-45d9-ad71-a0e6994c142c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "891cbf97-c246-4462-b59e-75f1d153100e",
      "evidence": "table/data: Company Drug Target/MOA Route of Administration Phase 1 Phase 2 Phase 3 Commercial",
      "confidence": 0.7
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "994e67b0-0576-4841-8fc8-e068bf99bd80",
      "evidence": "table/data: Company Drug Target/MOA Route of Administration Phase 1 Phase 2 Phase 3 Commercial",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 11,
      "beatId": "658ab0ae-6284-4b3b-b67a-e6c8bfbdd666",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 11-16 present APX3330 as a solution for Diabetic Retinopathy",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}